Loading clinical trials...
Loading clinical trials...
A Phase I Study of DEC205mAb-NY-ESO-1 Fusion Protein (CDX-1401) Given With Adjuvant PoIylCLC in Conjunction With 5-Aza-2'Deoxycytidine (Decitabine) in Patients With MDS or Low Blast Count AML
Conditions
Interventions
DEC-205/NY-ESO-1 Fusion Protein CDX-1401
Decitabine
+2 more
Locations
1
United States
Roswell Park Cancer Institute
Buffalo, New York, United States
Start Date
July 30, 2013
Primary Completion Date
June 9, 2015
Completion Date
March 21, 2016
Last Updated
July 22, 2022
NCT05564390
NCT03050268
NCT07320235
NCT06439199
NCT06782542
NCT05886049
Lead Sponsor
Roswell Park Cancer Institute
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions